Eos SENOLYTIX - Investor Relations https://validator.w3.org/feed/docs/rss2.html Pulmatrix and Eos merge to advance gerotherapeutics Vitalist Bay – Lighthaven, Berkeley Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses 2nd Annual Obesity & Cardiometabolic Innovation Forum (#Sachs_OCIF) The 17th World Congress on Targeting Mitochondria 2026 Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum Press Releases Events & Presentations News Founders Longevity Forum – London Investing in the Age of Longevity GEROSCIENCE-ICFSR2025 Task Force on Pre-Clinical and Clinical Trials International Conference on Frailty and Sarcopenia Research 2025 Founders Longevity Forum – Singapore The Cure for Aging SENOTHERAPEUTICS SUMMIT 2025 Longevity Investors Conference Longevity Biotechnology Association’s (LBA) Investors Conference Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity Events & Presentations2 Founders Longevity Forum in London MD Anderson and Phoenix SENOLYTIX announce cross-licensing agreement of CaspaCIDe™ for cell and gene therapies Brent Saunders Appointed as Advisory Board Chairman Sample Page Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan Science and Technology Contact Us Investor Relations – Eos SENOLYTIX